Details

Autor(en) / Beteiligte

• Nishimori, Hisakazu
• Matsuo, Keitaro
• Maeda, Yoshinobu
• Nawa, Yuichiro
• Sunami, Kazutaka
• Togitani, Kazuto
• Takimoto, Hidetaka
• Hiramatsu, Yasushi
• Kiguchi, Toru
• Yano, Tomofumi
• Yamane, Hiromichi
• Tabayashi, Takayuki
• Takeuchi, Makoto
• Makita, Masanori
• Sezaki, Nobuo
• Yamasuji, Yoshiko
• Sugiyama, Haruko
• Tabuchi, Takahiro
• Kataoka, Itaru
• Fujii, Nobuharu
• Ishimaru, Fumihiko
• Shinagawa, Katsuji
• Ikeda, Kazuma
• Hara, Masamichi
• Yoshino, Tadashi
• Tanimoto, Mitsune

Titel

The effect of adding rituximab to CHOP-based therapy on clinical outcomes for Japanese patients with diffuse large B-cell lymphoma: a propensity score matching analysis

Ist Teil von

• International journal of hematology, 2009-04, Vol.89 (3), p.326-331

Ort / Verlag

Tokyo: Springer Japan

Erscheinungsjahr

2009

Link zum Volltext

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• We conducted a retrospective analysis to evaluate the impact on clinical outcomes of adding rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) treatment for diffuse large B-cell lymphoma (DLBCL) patients in Japan. A propensity score method was used to compensate for the non-randomized study design. From January 2000 to December 2004, 378 patients who were newly diagnosed with DLBCL at 13 institutes were enrolled: 123 in the rituximab plus CHOP-based chemotherapy (R+) group, and 255 in the CHOP-based chemotherapy only (R−) group. The complete response rate was significantly higher in the R+ group than in the R− group (77.7 vs. 69.4%, P < 0.001). The progression-free survival (PFS) at 2 years was 62.4% in the R+ group and 57.0% in the R− group. The 2-year overall survival (OS) was 76.9% for the R+ group and 70.5% for the R− group. A multivariate analysis revealed that the addition of rituximab was a strong independent prognostic factor for PFS (hazard ratio 0.64, 95% CI 0.43–0.96, P = 0.031). A subgroup analysis revealed that R+ particularly benefited younger patients (hazard ratio 0.25, 95% CI 0.08–0.75, P = 0.013). IPI also showed significant impact for PFS (hazard ratio 1.82, 95% CI 1.55–2.14 for one score increase, P < 0.001) as well as OS (hazard ratio 2.10, 95% CI 1.71–2.57, P < 0.001). In summary, the addition of rituximab to CHOP-based chemotherapy results in better outcomes for Japanese DLBCL patients, particularly younger patients.